Laboratorios Liomont SA de CV:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Laboratorios Liomont SA de CV - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0491
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:メキシコ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Laboratorios Liomont SA de CV (Liomont) is a pharmaceutical company that develops medication products. The company offers prescription medication products, biotech products and over the counter products. It provides drugs in various therapeutic areas including analgesics, antiparasitic, antiviral, antibiotic, anti-inflammatory, antifungal, anti-obesity, cardiovascular, gastroenterology, anti-diabetics, respiratory, urological, musculoskeletal, gastrointestinal and cardiometabolic, among others. Liomont sells its products through a network of distributors in Mexico, Columbia, Dominican Republic, Equador, El Salvador, Guatemala, Panama, Peru and Venezuela. The company operates through its manufacturing facility located in Mexico. Liomont is headquartered in Mexico City, Mexico.

Laboratorios Liomont SA de CV – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Protein Sciences Enters into Licensing Agreement with Liomont for Flublok and Panblok 10
Oncobiologics Enters into Licensing Agreement with Liomont to Develop Biosimilar Monoclonal Antibody 12
Laboratorios Liomont Enters into Licensing Agreement with Selexis 13
Laboratorios Liomont SA de CV – Key Competitors 14
Laboratorios Liomont SA de CV – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Key Facts 2
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Laboratorios Liomont SA de CV, Deals By Therapy Area, 2012 to YTD 2018 8
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Protein Sciences Enters into Licensing Agreement with Liomont for Flublok and Panblok 10
Oncobiologics Enters into Licensing Agreement with Liomont to Develop Biosimilar Monoclonal Antibody 12
Laboratorios Liomont Enters into Licensing Agreement with Selexis 13
Laboratorios Liomont SA de CV, Key Competitors 14
Laboratorios Liomont SA de CV, Other Locations 15

List of Figures
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Laboratorios Liomont SA de CV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Laboratorios Liomont SA de CV:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NetEnt AB (NET B):企業の財務・戦略的SWOT分析
    Summary NetEnt AB (NetEnt), formerly Net Entertainment NE AB, is a gaming solution provider. The company offers netent live, pooled jackpots, branded games, casinomodule, back office, touch, live casino and extend. It provides services such as business intelligence, regulated markets, iGaming media …
  • Bellicum Pharmaceuticals Inc (BLCM):企業の財務・戦略的SWOT分析
    Summary Bellicum Pharmaceuticals, Inc. (Bellicum) is a clinical stage biopharmaceutical company, which is engaged in developing cellular immunotherapies for the treatment of cancer. The company develops its product candidates through its chemical induction of dimerization technology platforms in the …
  • PDS Biotechnology Corp-製薬・医療分野:企業M&A・提携分析
    Summary PDS Biotechnology Corp (PDS Biotechnology) is a biopharmaceutical company that develops immunotherapies and vaccines for cancer and infectious disease. The company uses versamune technology, which is immunostimulatory nanoparticle vaccine platform used for the development of cancer immunothe …
  • TOR Minerals International Inc (TORM):企業の財務・戦略的SWOT分析
    Summary TOR Minerals International Inc (TOR) is a chemical company that manufactures and distributes mineral and pigment products. The company provides products such as optiload, aluprem, haltex, and others. It also offers alumina trihydrate and boehmite halogen-free flame retardant and smoke suppre …
  • Cancer Research Technology Ltd.:企業のM&A・事業提携・投資動向
    Cancer Research Technology Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cancer Research Technology Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Hindustan Organic Chemicals Limited (HOCL):企業の財務・戦略的SWOT分析
    Hindustan Organic Chemicals Limited (HOCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Flisom AG:電力:M&Aディール及び事業提携情報
    Summary Flisom AG (Flisom) is a manufacturer and distributor of solar modules that produces and commercializes flexible solar modules based on CIGS photovoltaic technologies. The company offers products such as ultralight solar modules, thin film photovoltaic solar modules, lightweight solar modules …
  • Waterloo Industries Inc:企業の戦略的SWOT分析
    Waterloo Industries Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • MEG Energy Corp (MEG):石油・ガス:M&Aディール及び事業提携情報
    Summary MEG Energy Corp (MEG) is an oil and gas company that develops and produces from oil sands. The company operates Christina lake, May River and Surmont project. Its technologies comprise steam-assisted gravity drainage, cogeneration, Hi-Q field pilot and eMSAGP. MEG's Christina Lake project is …
  • HemaCare Corp (HEMA):企業の財務・戦略的SWOT分析
    Summary HemaCare Corp (HemaCare) is a provider of biological blood products and services. The company offers primary blood cells and tissues derived from normal and mobilized peripheral blood, cord blood, and bone marrow. It spans its expertise in isolations, custom cell collections and testing of p …
  • Advanced Micro Devices, Inc.:戦略・SWOT・企業財務分析
    Advanced Micro Devices, Inc. - Strategy, SWOT and Corporate Finance Report Summary Advanced Micro Devices, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • The Walt Disney Company (DIS):企業の財務・戦略的SWOT分析
    The Walt Disney Company (DIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • IntegraGen SA (ALINT):企業の財務・戦略的SWOT分析
    Summary IntegraGen SA (IntegraGen) is a developer and commercializer of molecular diagnostic tests for the treatment of autism and oncology. The company provides advanced genomic and bioinformatic services, including clinical research, basic and human genetic research, bioinformatics and bioanalysis …
  • Southern Company Gas:石油・ガス:M&Aディール及び事業提携情報
    Summary Southern Company Gas (SCG), formerly AGL Resources Inc., is an energy services holding company It operates through natural gas distribution, retail operations, wholesale services and midstream. The company serves utility customers through its regulated distribution subsidiaries in the states …
  • Regional Express Holdings Limited:企業の戦略・SWOT・財務情報
    Regional Express Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Regional Express Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Guernsey Electricity Limited:発電所・企業SWOT分析
    Guernsey Electricity Limited - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Cerus Corp (CERS):医療機器:M&Aディール及び事業提携情報
    Summary Cerus Corp (Cerus) is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes the INTERCEPT Blood System to enhance blood safety. INTERCEPT Blood System reduces the risk of transfusion-transmitted infections by inactivating a wide r …
  • Firstsource Solutions Ltd (FSL):企業の財務・戦略的SWOT分析
    Firstsource Solutions Ltd (FSL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Nodak Electric Cooperative, Inc.:企業の発電所・SWOT分析2018
    Nodak Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Guerbet SA (GBT):企業の財務・戦略的SWOT分析
    Guerbet SA (GBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆